Search
The Kids Research Institute Australia is leading a unique clinical trial in pet dogs that could pave the way for a new immunotherapy treatment for one of the most common childhood cancers, Sarcoma.
Children with aggressive brain cancers could soon have access to a significant new treatment option, using a unique antibody that stops cancer cells from repairing themselves.
The Kids Research Institute Australia researcher, Dr Anya Jones, will join some of the world’s brightest female scientists after being selected to take part in a global project to amplify the voices of women in science leadership.
Cancer Council WA has awarded a Post-Doctoral Fellowship to Dr Ben Wylie, for his project to help kids with sarcoma.
Join us as WA’s cancer research community comes together at the inaugural West Coast Cancer Meeting.
A report outlining key steps to tackle a common and aggressive childhood brain tumor is gaining rapid momentum after attracting international attention.
A new research scholarship to combat childhood brain tumours will be launched tonight in honour of two year old Perth toddler Ethan Davies.
Cancer researchers at The Kids for Child Health Research have developed a new test that can rapidly detect the loss of genes in cancer cells.
Brain cancer and leukemia are the most common cancers diagnosed in the pediatric population and are often treated with lifesaving chemotherapy. However, chemotherapy causes severe adverse effects and chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting and debilitating side effect.
Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.